Clinical Trials Logo

New Diagnosis Tumor clinical trials

View clinical trials related to New Diagnosis Tumor.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT04096066 Active, not recruiting - Multiple Myeloma Clinical Trials

A Trial That Compare Two Treatments in Newly Diagnosed Myeloma Patients Not Eligible for Transplant

KRdvsRd
Start date: July 1, 2019
Phase: Phase 3
Study type: Interventional

The combination of lenalidomide plus low-dose dexamethasone (Rd) is considered the new standard for elderly newly diagnosed multiple myeloma (NDMM) patients. The combination carfilzomib plus lenalidomide-dexamethasone (KRd) in relapsed-refractory MM patients improved the progression-free survival (PFS) of approximately 1 year compared to standard Rd treatment. In a small phase 2 trial (23 pts) the KRd combination in elderly NDMM pts showed a complete response (CR) rate of 79% and a PFS at 3 years of 80%. Cardiovascular adverse events are the most limiting toxicities, especially in elderly patients.